Heidi Henson
Heidi Henson's purchase track record
Heidi Henson has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/4/2024 | CATX | $100K | -31.8% | -15.6% | -1.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
CATX included in pre-market movers list. Perspective Therapeutics was listed among stocks moving lower in Monday's pre-market session. The company is currently trading near its 52-week low, with an RSI of 32.3 indicating oversold conditions. Analysts maintain an average price target of $12.29, which is significantly higher than the current market price.
Transaction History
| LSTA | ▲ Buy | Grant | 30,456 | $0 | 1/9/2026 | View on chart |
| LSTA | ▲ Buy | Grant | 15,789 | $0 | 1/9/2025 | View on chart |
| CATX | ▲ Buy | Open Market | 25,975 | $100K | 12/4/2024 | View on chart |
| LSTA | ▲ Buy | Grant | 19,480 | $0 | 1/9/2024 | View on chart |
| LSTA | ▲ Buy | Grant | 20,000 | $0 | 1/9/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Lisata reports first patient dose in MAR002 acromegaly trial
Lisata Therapeutics announced that its subsidiary Marea Therapeutics has given the first dose of MAR002 to a patient in a Phase 2 trial for acromegaly. This marks the first clinical exposure of the drug and represents a key step toward potential regulatory approval. The announcement highlights progress in Lisata’s development pipeline, though the company remains in early stages of product development.
Lisata reports first patient dose in MAR002 acromegaly trial. Lisata Therapeutics announced that its subsidiary Marea Therapeutics has given the first dose of MAR002 to a patient in a Phase 2 trial for acromegaly. This marks the first clinical exposure of the drug and represents a key step toward potential regulatory approval. The announcement highlights progress in Lisata’s development pipeline, though the company remains in early stages of product development.